Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
2.800
+0.070 (2.56%)
At close: Aug 22, 2025, 4:00 PM
2.780
-0.020 (-0.71%)
After-hours: Aug 22, 2025, 7:51 PM EDT
Editas Medicine Stock Forecast
Stock Price Forecast
The 10 analysts that cover Editas Medicine stock have a consensus rating of "Buy" and an average price target of $5.40, which forecasts a 92.86% increase in the stock price over the next year. The lowest target is $3.00 and the highest is $13.
Price Target: $5.40 (+92.86%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Editas Medicine stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 4 | 4 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 7 | 7 | 6 | 6 | 6 | 5 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 15 | 13 | 13 | 13 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $3 → $5 | Strong Buy | Maintains | $3 → $5 | +78.57% | Aug 15, 2025 |
| Baird | Baird | Buy Maintains $4 → $6 | Buy | Maintains | $4 → $6 | +114.29% | Aug 13, 2025 |
| Baird | Baird | Buy Maintains $8 → $4 | Buy | Maintains | $8 → $4 | +42.86% | May 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $3 | Strong Buy | Initiates | $3 | +7.14% | Apr 28, 2025 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $7 → $5 | Buy | Maintains | $7 → $5 | +78.57% | Dec 16, 2024 |
Financial Forecast
Revenue This Year
17.66M
from 32.31M
Decreased by -45.35%
Revenue Next Year
12.23M
from 17.66M
Decreased by -30.76%
EPS This Year
-2.10
from -2.88
EPS Next Year
-1.08
from -2.10
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 34.9M | 26.7M | 52.5M | ||
| Avg | 17.7M | 12.2M | 14.8M | ||
| Low | 9.0M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 7.9% | 51.0% | 329.4% | ||
| Avg | -45.4% | -30.8% | 21.3% | ||
| Low | -72.1% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.97 | -0.66 | -0.79 | ||
| Avg | -2.10 | -1.08 | -1.08 | ||
| Low | -2.18 | -1.35 | -1.22 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.